Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
11:00am, Thursday, 30'th Jul 2020
Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern TimeNEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical c
The Secondary Impact Of COVID-19 Pandemic Leads To Bigger Market Potential For Axsome Therapeutics
01:43pm, Monday, 27'th Jul 2020
Since the pandemic started, the market has overly-emphasized on COVID-19 vaccines but ignored its secondary impact: mental health.
These Stocks Would Have Doubled Your Money Last Year
11:10am, Saturday, 25'th Jul 2020
Axsome Therapeutics and EverQuote had two of the biggest stock gains in 2019. Are they still buys today?
Were Hedge Funds Right About Axsome Therapeutics, Inc. (AXSM)?
04:21pm, Thursday, 16'th Jul 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
Steven Cohen Homes in on Otonomy by Expanding Stake
05:15pm, Wednesday, 15'th Jul 2020
Guru ups bet in biotech focused on ear-related disorders Continue reading...
Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020
04:05pm, Wednesday, 15'th Jul 2020
Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.
Axsome's NDA for Depressive Disorder Drug on Track in Q420
04:16pm, Tuesday, 14'th Jul 2020
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder
11:00am, Monday, 13'th Jul 2020
NDA submission on track for 4Q 2020 NEW YORK, July 13, 2020 -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the.
Here's Why Axsome Therapeutics Fell 20.4% in the First Half of 2020
06:41pm, Wednesday, 08'th Jul 2020
One of the best investments of 2019 fell on hard times in the first six months of 2020, but it's not as bad as it seems.
3 “Perfect 10” Healthcare Stocks That Have Plenty of Growth on Tap
03:14pm, Tuesday, 07'th Jul 2020
Disconnected. This seems to be the best way to describe the current economic environment. Amid high levels of unemployment and tanking earnings, stocks aren’t just hanging in there, they’re chargi
What Kind Of Investors Own Most Of Axsome Therapeutics, Inc. (NASDAQ:AXSM)?
07:19pm, Friday, 03'rd Jul 2020
A look at the shareholders of Axsome Therapeutics, Inc. (NASDAQ:AXSM) can tell us which group is most powerful...
Axsome Therapeutics Inc (NASDAQ:AXSM) Director Purchases $51,025.00 in Stock
06:44am, Thursday, 02'nd Jul 2020
Axsome Therapeutics Inc (NASDAQ:AXSM) Director Mark Coleman purchased 650 shares of the stock in a transaction on Monday, June 29th. The shares were purchased at an average cost of $78.50 per share, f
Voloridge Investment Management LLC Acquires Shares of 7,285 Axsome Therapeutics Inc (NASDAQ:AXSM)
09:13am, Wednesday, 01'st Jul 2020
Voloridge Investment Management LLC acquired a new stake in shares of Axsome Therapeutics Inc (NASDAQ:AXSM) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange
Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation
04:49pm, Monday, 29'th Jun 2020
The FDA bestows a Breakthrough Therapy status on Axsome's (AXSM) AXS-05 for the treatment of Alzheimer's disease agitation. Shares rise.
